J Gastric Cancer.  2019 Jun;19(2):183-192. 10.5230/jgc.2019.19.e15.

Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy

Affiliations
  • 1Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan. m-kanda@med.nagoya-u.ac.jp

Abstract

PURPOSE
Due to adverse events, dose reduction or withdrawal of adjuvant chemotherapy is required for some patients. To identify the predictive factors for tolerability to postoperative adjuvant S-1 monotherapy in gastric cancer (GC) patients, we evaluated the predictive values of blood indicators.
MATERIALS AND METHODS
We analyzed 98 patients with pStage II/III GC who underwent postoperative adjuvant S-1 monotherapy. We retrospectively analyzed correlations between 14 parameters obtained from perioperative routine blood tests to assess their influence on the withdrawal of postoperative adjuvant S-1 monotherapy, within 6 months after discontinuation.
RESULTS
Postoperative adjuvant chemotherapy was discontinued in 21 patients (21.4%) within 6 months. Univariable analysis revealed that high preoperative albumin-bilirubin (ALBI) scores had the highest odds ratio (OR) for predicting the failure of adjuvant S-1 chemotherapy (OR, 6.47; 95% confidence interval [CI], 2.08-20.1; cutoff value, -2.696). The high ALBI group had a significantly shorter time to failure of postoperative adjuvant S-1monotherapy (hazard ratio, 3.48; 95% CI, 1.69-7.25; P=0.001). Multivariable analysis identified high preoperative ALBI score as an independent prognostic factor for tolerability (OR, 10.3; 95% CI, 2.33-45.8; P=0.002).
CONCLUSIONS
Preoperative ALBI shows promise as an indicator associated with the tolerability of adjuvant S-1 monotherapy in patients with pStage II/III GC.

Keyword

Gastric cancer; S-1; Adjuvant chemotherapy; Biomarker; Albumin-bilirubin score

MeSH Terms

Chemotherapy, Adjuvant
Drug Therapy
Gastrectomy*
Hematologic Tests
Humans
Odds Ratio
Retrospective Studies
Stomach Neoplasms

Figure

  • Fig. 1 (A) OS of patients with pStage II/III gastric cancer with or without 6 months of S-1 postoperative adjuvant monotherapy. (B) Preoperative study parameters and ORs. OS = overall survival; OR = odds ratio; HR = hazard ratio; CI = confidence interval; WBC = white blood cell; Neu = neutrophil count; TLC = total lymphocyte count; Plt = platelet count; TP = total protein; Alb = albumin; ChE = cholinesterase; T-Bil = total bilirubin; AST = aspartate aminotransferase; ALT = alanine aminotransferase; CCr = creatinine clearance; ALBI = albumin-bilirubin; PLR = platelet-lymphocyte ratio; PNI = prognostic nutritional index.

  • Fig. 2 (A) ORs of ALBI scores and its variables before surgery and postoperative adjuvant chemotherapy initiation and perioperative changes. (B) Time-to-treatment failure of postoperative adjuvant S-1 monotherapy with high and low ALBI scores. OR = odds ratio; ALBI = albumin-bilirubin; HR = hazard ratio; CI = confidence interval; Alb = albumin; T-Bil = total bilirubin.


Reference

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.
Article
2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357:1810–1820.
Article
3. André T, Tournigand C, Achille E, Tubiana-Mathieu N, Lledo G, Raoul Y, et al. Adjuvant treatment of colon cancer MOSAIC study's main results. Bull Cancer. 2006; 93:Suppl 1. S5–S9.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012; 379:432–444.
5. Sandra-Petrescu F, Herrle F, Burkholder I, Kienle P, Hofheinz RD. Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial. BMC Cancer. 2018; 18:369.
Article
6. Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019; 4:208–216.
Article
7. Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, et al. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Cancer. 2013; 16:133–139.
Article
8. Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2013; 20:2000–2006.
Article
9. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33:550–558.
Article
10. Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, et al. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes. 2016; 14:24.
Article
11. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017; 20:1–19.
12. Kanda M, Mizuno A, Tanaka C, Kobayashi D, Fujiwara M, Iwata N, et al. Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. Medicine (Baltimore). 2016; 95:e3781.
Article
13. Kanda M, Tanaka C, Kobayashi D, Uda H, Inaoka K, Tanaka Y, et al. Preoperative albumin-bilirubin grade predicts recurrences after radical gastrectomy in patients with pT2-4 gastric cancer. World J Surg. 2018; 42:773–781.
Article
14. Andreatos N, Amini N, Gani F, Margonis GA, Sasaki K, Thompson VM, et al. Albumin-bilirubin score: predicting short-term outcomes including bile leak and post-hepatectomy liver failure following hepatic resection. J Gastrointest Surg. 2017; 21:238–248.
Article
15. Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Lee YH, et al. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep. 2018; 8:4773.
Article
16. Ichikawa W. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer. 2006; 9:145–155.
Article
17. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005; 5:226–243.
Article
18. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol. 1996; 14:257–267.
Article
19. Miura K, Konishi J, Miyake T, Makita M, Hojo A, Masaki Y, et al. A host-dependent prognostic model for elderly patients with diffuse large B-cell lymphoma. Oncologist. 2017; 22:554–560.
Article
20. Gong J, Cho M, Fakih M. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol. 2017; 8:314–323.
Article
21. Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol. 2015; 9:1549–1560.
Article
22. Kanda M, Murotani K, Kobayashi D, Tanaka C, Yamada S, Fujii T, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015; 158:1573–1580.
Article
23. Imamura H, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y, et al. Effects of an oral elemental nutritional supplement on post-gastrectomy body weight loss in gastric cancer patients: a randomized controlled clinical trial. Ann Surg Oncol. 2016; 23:2928–2935.
Article
Full Text Links
  • JGC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr